Chemicals & Small Molecules

Lusvertikimab (OSE-127), a humanized IL7R monoclonal antibody, does not get internalized by target cells and inhibits IL7R heterodimerization along with subsequent downstream signaling. It demonstrates anti-leukemic properties and holds potential for research in B cell precursor acute lymphoblastic leukemia (BCP-ALL) [1].

Adebrelimab (SHR-1316), a humanized IgG4 monoclonal antibody targeting PD-L1 (PD-1/PD-L1), exhibits promising antitumor activity, notably in solid tumors and extensive-stage small-cell lung cancer (SCLC) [1] [2].

Anumigilimab (CSL-324) is a fully human therapeutic anti-G-CSFR antibody with potential anti-tumor activity for the study of inflammation.

Brazikumab (AMG 139), a human IgG2 monoclonal antibody, selectively targets the p19 subunit of IL-23 with a dissociation constant (K D) of 0.138 nM, indicating high affinity for human IL-23. It is employed in Crohn's disease research [1].

Brazikumab (AMG 139), a human IgG2 monoclonal antibody, selectively targets the p19 subunit of IL-23 with a dissociation constant (K D) of 0.138 nM, indicating high affinity for human IL-23. It is employed in Crohn's disease research [1].

Cergutuzumab amunaleukin (CEA-IL2v) is a CEA-targeted IL-2 variant immunocytokine for combination cancer immunotherapy with immunostimulatory and anti-tumor activities for the study of solid cancers.

Xeligekimab (GR 1501) is a fully human monoclonal antibody that selectively neutralizes IL-17A, has potential anti-inflammatory activity, and can be used to study plaque psoriasis.

Solitomab (AMG 110), a bispecific antibody targeting CD3 and EpCAM, is utilized in researching primary uterine and ovarian carcinosarcoma cancer [1] [2].

Socazolimab (ZKAB001), an anti-PD-L1 monoclonal antibody, demonstrates enduring safety and efficacy in treating recurrent or metastatic cervical cancer. Additionally, it shows promise for treating small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma, and osteosarcoma [1] [2] [3] [4] [5].